Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Only Private Industry Can Reach India's Rural Population As Government Focuses On Disease Prevention

This article was originally published in PharmAsia News

Executive Summary

HONG KONG - Trying to improve the quality of its healthcare services, India plans to reach out to its vast rural population while looking to create partnership opportunities within the private sector
Advertisement

Related Content

With No Big Push For R&D Or Infrastructure, Indian Budget Belies Pharma Industry Hopes
With No Big Push For R&D Or Infrastructure, Indian Budget Belies Pharma Industry Hopes
Indian Government Applauds 2010 Preventative Efforts That Lead To Drops In AIDS, Polio, TB
Indian Government Applauds 2010 Preventative Efforts That Lead To Drops In AIDS, Polio, TB
Sanofi-Aventis Closes In On Diabetics In India; Big Push On Rural Markets And New Launches
Good Quality Drugs At Affordable Costs: Indian Government Considers Universal Healthcare Among Various Options
Advertisement
UsernamePublicRestriction

Register

SC077212

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel